Clinical significance of determining plasma homocysteine: Case-control study on arterial and venous thrombotic patients

Croatian Medical Journal

Volumn 54, Issue 5, 2013, Pages 480-488

  Vučković, Biljana A ^a   Čabarkapa, Velibor S ^b   Ilić, Tatjana A ^b   Salatić, Iva R ^a   Lozanov Crvenković, Zagorka S ^c   Mitić, Gorana P ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b Clinical Centre of Vojvodina   (Serbia)

^c UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

ADOLESCENT; ADULT; ARTERY THROMBOSIS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; VEIN THROMBOSIS;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INCIDENCE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; ODDS RATIO; RISK FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84888413707     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2013.54.480     Document Type: Article

References (48)

1. Mahan CE, Fanikos J. New antithrombotics: The impact on global health care. Thromb Res. 2011;127:518-24. Medline:21529897 doi:10.1016/j.thromres.2011.03.022
2. Vuckovic B, Deric M, Iilic T, Canak V, Kojic-Damjanov S, Zarkov M, et al. Fibrinolytic parameters, lipid status and Lp(a) lipoprotein in ischemic stroke patients. Srp Arh Celok Lek. 2010;138 Suppl 1:12-7. Medline:20229676
3. E nghers MJ, vanHylckama AV, Rosendaal FR. Venous thrombosis in elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010;8:2105-10. Medline:20629943 doi:10.1111/j.1538- 7836.2010.03986.x
4. Smith SC, Milani RW, Arnett DK, Crouse JR, McDermott MM, Ridker PM. Atherosclerotic Vascular Disease Conference. Writing Group II: Risk Factors. Circulation. 2004;109:2613-6. Medline:15173043 doi:10.1161/01.CIR.0000128519.60762.84
5. Milosevic-Tosic M. Hyperhomocysteinemia as risk factor of occlusive vascular diseases with estimation of laboratory methods for homocysteine determination [in Serbian]. PhD thesis. School of Medicine, Novi Sad University; 2010.
6. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111- 28. Medline:5792556
7. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for metionin metabolism. J Clin Invest. 1976;57:1079-82. Medline:947949 doi:10.1172/JCI108350
8. Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, et al. Variability and determinants of total homocysteine concentrations in plasma in an elderly population. Clin Chem. 1998;44:102-7. Medline:9550566
9. H olmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta analysis of genetic studies and randomized trials. Lancet. 2011;378:584-94. Medline:21803414 doi:10.1016/S0140- 6736(11)60872-6
10. U eland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:1764-79. Medline:8375046
11. H errman W. Significance of hyperhomocysteinemia. Clin Lab Med. 2006;52:367-74.
12. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and double blind placebo-controlled trial. Atherosclerosis. 2003;166:379-86. Medline:12535752 doi:10.1016/S0021- 9150(02)00372-6
13. Michel G, Staub U, Schroeder G, Shih J; International Hcy group. Determination of homocysteine reference intervals: Data from the European Automated FPIA study. Clin Lab. 1999;45:651-6.
14. Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs. vitamin B12 and folate. Clin Chem. 2000;46:1277-83. Medline:10926922
15. Salatic I, Kiralj K, Mitic G, Veselinovic I, Vapa D. FV Leiden mutation and deep venous thrombosis in Vojvodina: a case-control study. J Med Biochem. 2011;30:51-4. doi:10.2478/v10011-010-0050-7
16. Yin G, Yan L, Zhang Z, Chen K, Jin X. C677T methylenetetrahydrofolate reductase gene polymorphism as a risk factor involved in venous thromboembolism: a population based case-control study. Mol Med Rep. 2012;6:1271-5. Medline:22992862
17. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-8. Medline:7475822 doi:10.1016/S0140-6736(95)92407-8
18. Boushey CJ, Beresford SAA, Omen GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-57. Medline:7563456 doi:10.1001/ jama.1995.03530130055028
19. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from meta-analysis. BMJ. 2002;325:1202-6. Medline:12446535 doi:10.1136/ bmj.325.7374.1202
20. Bonaa KH, Njolstad I, Ueland PM; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-88. Medline:16531614 doi:10.1056/NEJMoa055227
21. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77. Medline:16531613 doi:10.1056/NEJMoa060900
22. Faraci FM. Hyperhomocysteinemia: a million ways to lose control. Arterioscler Thromb Vasc Biol. 2003;23:371-3. Medline:12639825 doi:10.1161/01.ATV.0000063607.56590.7F
23. H ankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407-13. Medline:10437885 doi:10.1016/S0140- 6736(98)11058-9
24. Geisel J, Zimbelmann I, Schorr H, Knapp JP, Bodis M, Hubner U, et al. Defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med. 2001;39:698-704. Medline:11592436 doi:10.1515/CCLM.2001.115
25. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279- 98. Medline:1503807 doi:10.1146/annurev.nu.12.070192.001431
26. D udman NP. An alternative view of homocysteine. Lancet. 1999;354:2072-4. Medline:10636386 doi:10.1016/S0140- 6736(99)03383-8
27. Lentz SR. Homocysteine in health and disease. Cambridge: Cambridge University Press; 2001.
28. Zhang B, Qiu L, Fu M, Hu S. Interference in mevalonate pathway ameliorates homocysteine-induced endothelium dysfunction. Eur J Pharmacol. 2012;692:61-8. Medline:22796672 doi:10.1016/j. ejphar.2012.07.014
29. Sibinga NES. Channeling the homocysteine chapel. Blood. 2011;118:1717-9. Medline:21852445 doi:10.1182/blood-2011-06- 361360
30. Malleshappa K, Rajasekhar P, Jayalakshmi L. Association of inflammation biomarkers with homocysteine & lipid profile in obese young adults. Natl J Basic Med Sci. 2012;2:189-93.
31. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-50. Medline:9535670 doi:10.1056/NEJM199804093381507
32. H ofmann MA, Lalla E, Lu Y, Ryu Gleason M, Wolf BM, Tanji N, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107:675-83. Medline:11254667 doi:10.1172/JCI10588
33. U ngvari Z, Sarkadi-Nagy E, Bagi Z, Szollar L, Koller A. Simultaneously increased TxA(2) activity in isolated arterioles and platelets of rats with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 2000;20:1203-8. Medline:10807734 doi:10.1161/01. ATV.20.5.1203
34. N ahar A, Sabo C, Chitlur M, Ravindrainath Y, Lusher J, Rajpurkar M. Plasma homocysteine levels, methilene tetrahidrofolate reductase polymorphisms, and the risk of thromboembolism in children. J Pediatr Hematol Oncol. 2011;33:330-3 Medline:21602719. doi:10.1097/MPH.0b013e318219324f
35. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C?T polymorphism and risk of coronary heart disease: a metaanalysis. JAMA. 2002;288:2023-31. Medline:12387655 doi:10.1001/ jama.288.16.2023
36. Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients. Circulation. 2011;123:1763-70. Medline:21482964 doi:10.1161/ CIRCULATIONAHA.110.000588
37. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylentetrahydro-folate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9. Medline:8616944 doi:10.1161/01.CIR.93.1.7
38. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJP, Reitsma PH. The effect of a common methyleneterahydrofolate reductase mutation on the levels of homocysteine, folate, vitamin B 12 and on the risk of premature atherosclerosis. Atherosclerosis. 1998;141:161-6. Medline:9863549 doi:10.1016/S0021-9150(98)00156-7
39. Rimm EB, Stampfer MJ. Folate and cardiovascular disease: one size does not fit all. Lancet. 2011;378:544-6. Medline:21803413 doi:10.1016/S0140-6736(11)61057-X
40. H uang T, Zheng J, Chen Y, Yang B, Wanhlqvist ML, Li D. High consumption of O-3 polyunsaturated fatty acids decrease plasma homocysteine: A meta-analysis of randomized, placebo-controlled trials. Nutrition. 2011;27:863-7. Medline:21501950 doi:10.1016/j. nut.2010.12.011
41. Chiuve SE, Goavannucci EL, Hankinson SE, Zeisel SH, Dougherty LW, Willett C, et al. The association between betaine and choline intakes and the plasma concentrations of homocysteine in women. Am J Clin Nutr. 2007;86:1073-81. Medline:17921386
42. Sunder-Plassmann G, Fodinger M. Genetic determinants of the homocysteine level. Kidney Int Suppl. 2003;84:S141-4. Medline:12694331 doi:10.1046/j.1523-1755.63.s84.52.x
43. Frosst P, Blom HJ, Miols R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-3. Medline:7647779 doi:10.1038/ng0595-111
44. Mirkovic D, Majkic-Singh N, Ignjatovic S. Homocysteine: chemistry, metabolism and role in pathophysiological processes [in Serbian]. Jugoslav Med Biohem. 2003;22:127-40. doi:10.2298/JMH0302127M
45. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylentetrahydro-folate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9. Medline:8616944 doi:10.1161/01.CIR.93.1.7
46. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJP, Reitsma PH. The effect of a common methyleneterahydrofolate reductase mutation on the levels of homocysteine, folate, vitamin B 12 and on the risk of premature atherosclerosis. Atherosclerosis. 1998;141:161-6. Medline:9863549 doi:10.1016/S0021-9150(98)00156-7
47. Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E. Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteinelowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med. 2007;146:761-7. Medline:17470822 doi:10.7326/0003-4819-146-11-200706050- 00157
48. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med. 2006;354:1629-32. Medline:16531615 doi:10.1056/NEJMe068060